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Brief Definit ive Report
Although much effort in the field of oncology 
has focused on canonical oncogenes and tumor 
suppressor genes, the importance of cancer 
cell metabolism is growing in appreciation 
(DeBerardinis et al., 2008; Vander Heiden et al., 
2009). Known as the Warburg effect (Warburg 
1956), this reprogramming of gene expression 
that alters glucose metabolism enables cells to 
suppress apoptotic signaling, to grow in hypoxic 
environments, and to use more glucose for 
anabolic processes rather than oxidative phos-
phorylation, even when oxygen is not limiting 
(Ferguson and Rathmell, 2008).
Pyruvate kinase (PK) catalyzes the conver-
sion of phosphoenolpyruvate (PEP) and ADP to 
pyruvate and ATP and regulates glucose carbon 
flux in the cell. In addition to the liver (L) and red 
blood cell (R) isoforms, two isoforms of pyruvate 
kinase are found in mammals: M1, which is ex-
pressed in most adult tissues, and M2, which is 
expressed predominantly in embryonic tissue and 
tumors (Jurica et al., 1998). PKM1 and PKM2 
differ by only 23 amino acids within a 56-residue 
alternatively spliced exon (9 or 10, respectively; 
Noguchi et al., 1986). These amino acids in the 
M2 isoform constitute an allosteric pocket unique 
to PKM2 that allows it to bind its activator, 
fructose 1,6-bisphosphate (FBP), and be regu-
lated by phosphotyrosine-based growth signals 
(Dombrauckas et al., 2005; Christofk et al., 2008b).
Pyruvate kinase activity can be modulated 
not only by alternative splicing (Clower et al., 
2010; David et al., 2010) but also by allostery 
(Boxer et al., 2010; Vander Heiden et al., 2010a). 
PKM2 exists as either an active tetramer or a 
relatively inactive dimer or monomer. The lat-
ter form is commonly expressed at high levels 
in tumor cells (Ugurel et al., 2005), and this 
conformation is favored by binding of phospho-
tyrosinated proteins, which displace FBP, the 
glycolytic metabolite that induces formation 
of the tetrameric form (Ashizawa et al., 1991). 
The low activity of the monomer and dimer 
forms causes an accumulation of PEP and other 
glycolytic intermediates, resulting in the redirec-
tion of glucose to serve as a carbon source for 
macromolecule biosynthesis, which is important 
for cell division (Christofk et al., 2008a).
Recently, it was shown that cancer cells use an 
alternative glycolytic pathway (Vander Heiden 
et al., 2010b). Specifically, the decreased pyruvate 
kinase activity associated with PKM2 expression 
allows PEP-dependent histidine phosphorylation 
of the upstream glycolytic enzyme phosphoglyc-
erate mutase, decoupling generation of ATP 
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The development of cancer-specific therapeutics has been limited because most healthy cells 
and cancer cells depend on common pathways. Pyruvate kinase (PK) exists in M1 (PKM1) and 
M2 (PKM2) isoforms. PKM2, whose expression in cancer cells results in aerobic glycolysis and 
is suggested to bestow a selective growth advantage, is a promising target. Because many 
oncogenes impart a common alteration in cell metabolism, inhibition of the M2 isoform might 
be of broad applicability. We show that several small interfering (si) RNAs designed to target 
mismatches between the M2 and M1 isoforms confer specific knockdown of the former, 
resulting in decreased viability and increased apoptosis in multiple cancer cell lines but less  
so in normal fibroblasts or endothelial cells. In vivo delivery of siPKM2 additionally causes 
substantial tumor regression of established xenografts. Our results suggest that the inherent 
nucleotide-level specificity of siRNA can be harnessed to develop therapeutics that target 
isoform-specific exons in genes exhibiting differential splicing patterns in various cell types.
© 2012 Goldberg and Sharp This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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liver (Akinc et al., 2008; Love et al., 2010) and ovaries (Huang 
et al., 2009; Goldberg et al., 2011) in vivo.
The primary screen used a luminescent assay in which the 
signal was proportional to the amount of ATP present, a surro-
gate for viability. To measure the number of intact viable cells 
directly, a fluorogenic, cell-permeant peptide substrate was used 
as a complementary assay. Viability and Caspase3/7-mediated 
apoptosis were measured in all three cell lines. Although their 
relative efficacy varies slightly between cell lines, si27, si155, and 
si156 consistently reduce cell viability and increase apoptosis in 
each cancer line examined, whereas the negative control does 
not. That three independent sequences targeting the M2 iso-
form confer the same phenotype supports the specificity of the 
effect, as each was confirmed to impart robust silencing of the 
target gene. Importantly, these data indicated that the decreased 
relative viability is mostly attributable to programmed cell death 
rather than simply to inhibition of proliferation. Progressing 
toward in vivo studies, we elected to focus on si156, because it 
was among the most active in all cell lines tested.
Real-time PCR was used to confirm that the knockdown 
was robust and specific and was correlated to phenotype. A direct 
proportionality between knockdown and efficacy was observed. 
The minimum knockdown required for efficacy was shown to be 
rather high. An 90% mRNA silencing (2.5 nM) was required 
to observe a 50% decrease in cell viability. A >95% mRNA 
silencing (5 nM) conferred a >95% decrease in HCT116 cell 
viability (Fig. 2 D). That strong silencing is required to impart a 
phenotype is supported by previous efforts to inhibit PKM2 
activity specifically with small molecules, which proved difficult 
(Vander Heiden et al., 2010a). With no effect on PKM1 levels, 
si156 conferred as much as a 97% knockdown of PKM2 mRNA 
at a dose of 5 nM. It was additionally confirmed that this knock-
down at the mRNA level translated to knockdown at the protein 
level (Fig. 2 E). Although the levels of PKM1 could not be mea-
sured directly, as an antibody against this protein was not com-
mercially available, total PK was reduced in HCT116, HepG2, 
and SKOV3 cells treated with si156, and PKM2 was specifi-
cally knocked down in all of these cell lines. Moreover, the 
knockdown resulted in a twofold decrease in lactate produc-
tion, providing functional biochemical support for an on-target 
effect (Fig. 2 F). The residual lactate production is probably 
attributable to the presence of either the M1 isoform or residual 
PKM2 protein.
The NCI-60 is a panel of human tumor cell lines that are 
well characterized and broadly used in drug screening. The con-
stituent lines represent multiple types of cancer, including brain, 
breast, colon, lung, ovarian, renal, and skin cancers, and sundry 
underlying genetic insults, including K-ras, B-Raf, and PIK3CA 
activation as well as p53, p16, and PTEN inactivation. Microarray 
data show that the cell lines used have a wide range of PKM2 ex-
pression levels, from relatively low (HCT-15, T47D) to relatively 
high (IGROV-1, U251) (http://dtp.cancer.gov/mtweb).
To confirm that the effects of si156 on cell viability are not 
highly dependent on the type of causal mutations, 10 cell lines 
from the NCI-60 were treated with siControl or si156, and the 
effects of the siRNAs on viability and Caspase3/7-mediated 
from PEP-mediated phosphotransfer. The level of PKM2 expres-
sion might be important in balancing the two glycolytic pathways. 
We find that targeting with a PKM2-specific small interfering (si) 
RNA inhibits the growth of many cancer cell lines.
The knockdown of pyruvate kinase by shRNA targeting 
sequences common to both the M1 and M2 isoforms resulted 
in decreased rates of glucose metabolism and reduced cell prolif-
eration (Christofk et al., 2008a). Although rescue of PKM2 
enhances tumor growth, the effect of knocking down PKM2 
specifically has yet to be investigated. To this end, we designed 
siRNAs that are specific to PKM2 and examined their ability 
to confer specific knockdown, to decrease cell proliferation, to 
induce apoptosis, and to inhibit tumor xenograft growth.
RESULTS AND DISCUSSION
Identification of M2-specific siPKs
Sequences that would target the M2 isoform of pyruvate kinase 
specifically were identified (Fig. 1 A). A custom library of 
siRNAs that tiled exon 10, which is included exclusively in the 
M2 isoform, was screened (Table S1). The ability of each siRNA 
to decrease cell viability in the human colon cancer cell line 
HCT116 was assessed (Fig. 1 B). Notably, very few siRNAs 
(<7%) actually generated a phenotype, as defined by <20% sur-
vival relative to untreated cells. Three sequences from the tiling 
library—si27, si155, and si156—conferred a particularly potent 
inhibition of survival or proliferation (<5% survival). The ability 
to inhibit proliferation was observed to correlate with the extent 
of target knockdown, supporting an on-target effect.
siControl, a sequence that targets firefly luciferase, was 
used as a negative control. siPK, a commercially available se-
quence which targets both PKM1 and PKM2, was used as a 
positive control. To maximize the specificity of the library, 
ON-TARGETplus siRNAs were used to reduce off-target 
effects (Jackson et al., 2006). Specifically, the sense strand is 
modified to prevent interaction with RISC and favor anti-
sense strand uptake, and the antisense strand seed region is 
modified to minimize seed-related off targeting.
To demonstrate that the effects imparted by the most 
efficacious siRNAs were a result of the knockdown of the 
M2 isoform and not to the knockdown of PKM1, isoform-
specific real-time PCR was performed using primers that 
were designed to amplify either isoform individually or total 
pyruvate kinase (Fig. 2 A). The knockdown of PKM2 was 
both specific and robust for si27, si155, and si156. As ex-
pected, siPK resulted in potent knockdown of both PKM1 
and PKM2. The pronounced changes at the mRNA level 
indicate that there is efficient uptake of siRNA.
siPKM2 induces apoptosis specifically in cancer cell lines
Next, the effect of the three most active siRNAs on viability 
and apoptosis was examined in HCT116, HepG2, and SKOV3 
cells (Fig. 2, B and C). HepG2, a hepatocellular carcinoma cell 
line, and SKOV3, an ovarian carcinoma cell line, were selected 
to complement HCT116, in which the original screen had 
been performed, because the current most advanced siRNA 
delivery systems successfully deliver RNAi therapeutics to the 
 o
n
 April 18, 2012
jem.rupress.org
D
ow
nloaded from
 
Published January 23, 2012
JEM Vol. 209, No. 2 219
Br ief Definit ive Repor t
Importantly, we tested whether the effect of si156 on via-
bility is specific to cancer cell lines. Adult skin fibroblasts and 
human umbilical vein endothelial cells were grown in vitro at 
low passage number and transfected with siControl or si156. 
Unlike most differentiated cells, these primary cells actively 
proliferate in vitro and express PKM2. We sought to verify 
that the M2 isoform was being specifically knocked down at 
apoptosis were determined (Fig. 3, A and B). In all 10 cell lines, 
viability is drastically reduced among the cells treated with si156 
relative to those treated with siControl, and it is confirmed 
that the decreased viability is mostly attributable to the in-
duction of apoptosis, regardless of the cells’ growth rates. The 
extent of apoptotic induction varies between the cell lines, but 
up-regulation of apoptosis was observed in all cases.
Figure 1. The screening of a tiling siRNA library reveals sequences that can discriminate between the M1 and M2 isoforms of pyruvate kinase.  
(A) The sequences of the M1 and M2 isoforms of pyruvate kinase are shown. Mismatches are highlighted in yellow. (B) The viability of HCT116 cells for each  
member of the siPKM2 library is shown relative to the no treatment control. Cells were transfected with 5 nM siRNA at 0, 48, and 96 h and were assayed  
after 6 d. Transfections were performed in technical quadruplicate on two independent occasions. The three most active siRNA sequences are highlighted in red.  
NT, no treatment.
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Figure 2. The knockdown of the M2 isoform of pyruvate kinase mRNA by si27, si155, and si156 is potent and specific. (A) HCT116 cell were 
transfected with 5 nM siRNA. Duplicate biological samples were collected 48 h after transfection. Quantitative real-time PCR primers were designed to 
amplify total PKM, PKM1 only, or PKM2 only from HCT116 total RNA. HCT116, HepG2, and SKOV3 cells were transfected with 5 nM siRNA at 0, 48,  
and 96 h. (B and C) Cells were assayed for cell viability (B) and apoptosis (C) after 6 d. Results are normalized relative to the no treatment control. Trans-
fections were performed in technical triplicate on two independent occasions. NT, no treatment. siPK, siRNA targeting both M1 and M2 isoforms. siControl, siRNA 
targeting firefly luciferase. Error bars denote standard deviation. (D) HCT116 cells were transfected with serial dilutions of si156 at 0, 48, and 96 h.  
Cells were assayed for cell viability after 6 d. Results are normalized relative to the no treatment control. Transfections were performed in technical  
quadruplicate on two independent occasions. Error bars denote standard deviation. (E) Lysates were collected from HCT116, HepG2, and SKOV3 cells 48 h 
after transfection with 5 nM siRNA. Blots were probed with antibodies targeting either total PKM or PKM2. Duplicate biological samples were collected 
for HepG2 and SKOV3, the cell lines used in the xenograft experiment. NT, no treatment. Vinculin was used as a loading control. (F) Effect of si156 on 
lactate production in HCT116 cells. The assay was performed 48 h after cells were transfected with 5 nM siRNA. Results are normalized to the no treat-
ment control, and lactate production is further normalized to cell number. The experiment was performed in biological and technical duplicate on two 
independent occasions. Error bars denote standard deviation.
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the phenotype of decreased cell growth is observed only in the 
former. Thus, the difference in phenotype is owing to the in-
herent biology of the cell types rather than the inability of the 
siRNA to impart posttranscriptional gene silencing.
siPKM2 leads to regression of tumor volume
A member of the lipid-like class of materials dubbed lipi-
doids (Akinc et al., 2008) was used to encapsulate and de-
liver siRNA as nanoparticles to the xenograft tumors. The 
selected lipidoid, 98N12-5(1), has previously been shown to 
knock down multiple hepatic genes (Akinc et al., 2008) as 
well as a putative oncogene in vivo, resulting in reduction of 
tumor volume and extension of survival in three mouse 
models of ovarian cancer (Huang et al., 
2009; Goldberg et al., 2011).
We evaluated the efficacy of the 
siRNA treatments in vivo using xenograft 
models of liver (HepG2) and ovarian 
(SKOV3) carcinomas that were injected 
subcutaneously in SCID mice. When the 
induced tumors were 200 mm3 in vol-
ume, the mice were randomly divided 
the mRNA level (Fig. 4 A). Notably, despite the presence 
of PKM2 knockdown, which was also confirmed at the pro-
tein level (Fig. 4 B), an examination of cell viability revealed 
that treatment with si156 did not have a detrimental effect on 
survival for these noncancerous cells (Fig. 4 C). It is possible 
that after silencing of PKM2, the level of expression of PKM1 
in normal cells is adequate for viability, whereas this is not the 
case for transformed cells. Alternatively, evidence is emerging 
that there are noncatalytic roles for PKM2 in the cell, includ-
ing activation of VEGF (Semenza, 2011). Cancer cells may be 
more sensitive to these perturbations than normal cells. The 
extent of silencing at the mRNA level is comparable be-
tween HCT116 cancer cells and SF372 adult fibroblasts, yet 
Figure 3. Cancer cells are addicted to 
metabolic reprogramming by PKM2. 10 
members of the NCI-60, representing multiple 
types of cancer and numerous underlying 
genetic insults, were transfected with 5 nM 
siControl or si156 at 0, 48, and 96 h. Cell  
viability (A) and apoptosis (B) were determined 
after 6 d. Results are normalized to the no 
treatment control, and apoptosis is further 
normalized to cell number. Transfections were 
performed in technical quadruplicate on two 
independent occasions. NT, no treatment. 
Error bars denote standard deviation.
Figure 4. si156 does not reduce the viabil-
ity of normal human primary cells. (A) The 
knockdown of the M2 isoform of pyruvate  
kinase mRNA by si156 is confirmed in SF372  
human adult skin fibroblasts and human umbili-
cal vein endothelial cells (HUVECs). Primers were 
designed to amplify total PKM, PKM1 only, or 
PKM2 only. Duplicate biological samples were 
collected 48 h after transfection with 5 nM 
siRNA, and each sample was assayed in techni-
cal triplicate. (B) Lysates were collected from 
SF372 and HUVE cells 48 h after transfection 
with 5 nM siRNA. Blots were probed with anti-
bodies targeting either total PKM or PKM2.  
NT, no treatment. Vinculin was used as a loading 
control. (C) Relative cell viability was determined 
after six days. SF372 and HUVE cells were trans-
fected with 5 nM siRNA at 0, 48, and 96 h. 
Transfections were performed in technical quad-
ruplicate on two independent occasions. NT, no 
treatment. Error bars denote standard deviation.
 o
n
 April 18, 2012
jem.rupress.org
D
ow
nloaded from
 
Published January 23, 2012
222 PKM2 knockdown induces apoptosis and tumor regression | Goldberg and Sharp
fell below the standard curve and matched baseline levels, 
indicating that the observed effect was not conferred by an 
interferon-induced stimulation of an immune response.
siPKM2 is an example of isoform-specific RNAi
Although multiple available siRNA design algorithms did not 
predict any sequences within alternative exon 10 that would 
mediate robust silencing, we have identified multiple siRNAs 
that afford potent and specific silencing of the M2 isoform 
of pyruvate kinase. An inspection of the 10 top performing 
sequences reveals that the number of mismatches between 
the M1 and M2 isoforms ranges from 4 to 13. 5 of these 10 
sequences contain mismatches at one of the critical central 
positions 10 or 11, which have been shown to be important 
in conferring specificity (Wang et al., 2008b). We observed 
one “hot spot”: two of the top three siRNAs target con-
secutive 19-mers (si155 and si156). We also observed one 
“warm spot”: three siRNAs work moderately well over a 
sequence that spans 23 nucleotides (si83, si85, and si87).
Recent analysis of transcriptomes indicates that >90% of all 
human genes are expressed as alternatively spliced isoforms 
(Wang et al., 2008a). The ability to target one isoform of a gene 
effectively is inherent of siRNA technology. This work repre-
sents the first specific siRNA targeting of the M2 isoform of 
pyruvate kinase at the mRNA level and demonstrates that this 
knockdown can induce caspase-mediated apoptosis. The com-
bination of shPK and chemotherapy has been reported to 
increase the efficacy of the latter (Shi et al., 2010; Guo et al., 
2011). These studies, however, used a sequence that targets both 
the M1 and M2 isoforms. As a consequence, the results of these 
studies cannot be attributed specifically to M2 knockdown.
A small molecule drug that targets pyruvate dehydrogenase 
kinase was reported to affect cancer cell metabolism (Bonnet 
et al., 2007), confirming that metabolic modulation may be a 
viable therapeutic approach in the treatment of glioblastoma 
(Michelakis et al., 2010). Notably, small molecule antagonists 
of FBP binding by PKM2 may be insufficient to provide a 
complete abrogation of the role of PKM2 in cancer, as PKM2 
has been demonstrated to interact and cooperate with Oct-4 to 
regulate transcription in a manner that is seemingly unrelated 
to metabolism (Lee, et al., 2008). Indeed, PKM2 appears 
to have noncatalytic roles in the cell (Mazurek, 2011), so 
silencing PKM2 with siRNA may have therapeutic effects 
beyond that possible with a small molecule.
Off-target effects as a result of miRNA-type targeting are 
not likely to be responsible for the observed effects. Multiple 
sequences—containing different seed regions—addressing the 
same target were shown to confer the same phenotype in cancer 
cell lines. Furthermore, the extent of induction of apoptosis 
roughly correlated with the degree of knockdown. The knock-
down was shown to repress lactate production, confirming that 
the siRNA modulated metabolism. The siRNAs included 
chemical modifications that have been shown to minimize off-
target effects. Immunostimulation was not implicated in the 
observed tumor regression and certainly could not account 
for the specific inhibition in cell culture.
into separate groups and treated intratumorally twice per 
week for a period of 3 wk with either siControl or si156. 
Local administration was used to ensure effective delivery.
Compared with the control treatment, si156 showed 
activity against established xenograft tumors. Tumor regres-
sion was observed after two to three doses (10 d) for tumors 
receiving the siPKM2 treatment. The trial was halted when 
the control group had to be euthanized. At the end of the 
trial (day 20, six treatments), the mean ± SD (n = 4) tumor 
volumes were 541 ± 107 and 83 ± 84 mm3 for HepG2 
tumors and 348 ± 102 and 88 ± 110 mm3 for SKOV3 tumors 
for siControl and si156, respectively (Fig. 5, A and B).
Treatment with si156 prevented tumor expansion and 
even resulted in a volume reduction. Indeed, nearly all of 
the measured volume in the siPKM2-treated mice could be 
attributed to scar tissue caused by the intratumoral injections, 
as determined by attempted tumor recovery after the animals 
were sacrificed. There was no remnant of HepG2 tumor in 
half of the si156-treated animals, and there was no remnant 
of SKOV3 tumor in three quarters of the si156-treated 
animals. In the latter case, recovered tumor tissue was sec-
tioned and visualized by TUNEL staining (Fig. 5 C). si156-
treated tumors displayed significantly higher levels of apoptosis.
Finally, to confirm that the effect was mediated specifi-
cally by the RNAi pathway and not by an innate immune 
response (Kleinman et al., 2008), which can be sequence specific 
(Hornung et al., 2005), serum was collected from SCID mice 
treated with PBS, formulated siControl, or formulated si156, 
and interferon- levels were examined by ELISA. All samples 
Figure 5. Administration of lipidoid-formulated si156 results in a 
reduction in volume of established tumors. (A) HepG2. (B) SKOV3. 
Error bars denote SEM (n = 4). The size difference between the treatment 
and control groups is significant by two-tailed Student’s t test at day 20. 
P = 0.0005 and P = 0.0133, respectively. (C and D) TUNEL staining con-
firms induction of apoptosis in vivo. Sections of SKOV3 tumors from mice 
treated with lipidoid-formulated siControl (C) or si156 (D) are shown. 
Blue, DAPI; red, TUNEL. Bars, 250 µm.
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was repeated at 48 and 96 h. For the NCI-60 cell lines, 2,000 cells were seeded 
per well.
Assessment of apoptosis. 5,000 cells per well were seeded in 96-well 
plates (Falcon) and transfected with 5 nM siRNA using HiPerFect Transfec-
tion Reagent (QIAGEN). Relative apoptosis was determined at 144 h by 
Caspase-Glo 3/7 using the Apotox-Glo Assay (Promega). To retain knock-
down of PKM2, siRNA transfection was repeated at 48 and 96 h. For the 
NCI-60 cell lines, 2,000 cells were seeded per well.
Lactate assay. Lactate production was measured using a colorimetric assay 
kit (BioVision). 150,000 HCE116 cells were seeded in 12-well plates (Corning) 
and transfected with 5 nM siRNA using HiPerFect Transfection Reagent 
(QIAGEN). After 48 h, the subconfluent cells were washed three times with 
PBS. Krebs-Ringer-Hepes buffer supplemented with 10 mM glucose was 
added, and aliquots of media from each well were assessed 30 min later for 
the amount of lactate present. The cells were counted with a hemocytometer 
and by CellTiterGlo to normalize.
In vivo siPKM2 efficacy study. SCID mice (4 wk old) were purchased 
from Taconic. All in vivo experimentation was performed under the super-
vision of the Division of Comparative Medicine (DCM), Massachusetts 
Institute of Technology, and in compliance with the Principles of Labora-
tory Animal Care of the National Institutes of Health. HepG2 and SKOV3 
were obtained from American Type Culture Collection.
Anti-tumor efficacy was evaluated in SCID mice induced with HepG2 
and SKOV3 tumors on the left and right hind flanks, respectively, with a single 
s.c. injection of 2.5 × 106 cells. Mice were randomized when the tumors were 
approximately 200 mm3 in volume and were subjected to treatment with 
either siControl or si156, formulated with 98N12-5(1) as previously described 
(Akinc et al., 2008; n = 4 per group). The therapy was given in the form of an 
intratumoral injection twice a week at a dosage of 100 µg (1 mg/kg/100 mm3 
tumor volume). Day 0 indicates that start of treatment. Measurements 
of tumor volume were made every 2 d using the equation: tumor volume = 
(width2 × length)/2. The mice were monitored for up to 22 d and were 
euthanized when the tumor burden was deemed to be excessive by the DCM. 
A two-tailed Student’s t test was used for comparison of tumor sizes.
For histology, tumors were harvested from mice at the end of the trial 
(day 22), frozen in OCT (80°C), and cut into 5-µm sections for analysis. 
Sections were fixed (5% formaldehyde) and permeabilized with cold ethanol 
(70% volume). TUNEL assay was performed according to the manufacturer’s 
instructions (Invitrogen), and the nuclei were stained with Hoechst. Sections 
were examined with a DeltaVision confocal (Applied Precision) at 20×.
Immunostimulation study. SCID mice (Taconic) were administered 
PBS, 98N12-5(1)–formulated siControl, or 98N12-5(1)–formulated si156 at a 
dosage of 100 µg via subcutaneous injection (n = 3 per group). To measure 
serum interferon- levels, blood was collected from mice 6 h after injection 
by cardiac puncture. The level of interferon- was measured by ELISA 
according to the manufacturer’s protocol (PBL). The assay was performed in 
biological and technical triplicate.
Online supplemental material. Table S1 lists the tiling siRNA sequences 
designed to silence PKM2. Every possible 19-mer siRNA containing at least 
one mismatch between the M1 (exon 9) and M2 (exon 10) isoforms of 
human pyruvate kinase is represented. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20111487/DC1.
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Previous work demonstrated that the M2 isoform of pyru-
vate kinase is important for cancer metabolism and tumor 
growth (Christofk et al., 2008a), suggesting that it might be 
a good drug target. We have illustrated that it can be effectively 
targeted in a specific manner by siRNA and that this targeting 
induces apoptosis in cancer cell lines. It is noteworthy that 
glioblastoma cells (U251), which are known to retain high ex-
pression of the more efficient M1 isoform (Clower et al., 2010; 
David et al., 2010), also undergo apoptosis when the M2 iso-
form is knocked down despite the fact that they should still 
have efficient glycolytic flux through the action of the M1 iso-
form. This contrasts with the study reporting that expression 
of the M1 isoform is sufficient to rescue tumor formation, 
wherein tumor growth simply occurred at a slower rate than 
when the M2 isoform was expressed (Christofk et al., 2008a).
This work illustrates an example of the utility of RNAi in 
discriminating between closely related enzyme isoforms at the 
nucleotide level that may be difficult to achieve by traditional 
approaches. Several findings are worthy of emphasis. It is surpris-
ing that inhibiting the production of an enzyme that contributes 
to a pro-proliferative phenotype owing to its decreased activity 
should result in apoptosis. Finally, the findings are generalizable 
across divergent tumor types and etiologies. The results suggest 
that most tumor cells have pathways that converge on this node.
MATERIALS AND METHODS
Cell culture. Cells were maintained at 37°C and 5% CO2 in Dulbecco’s 
modified Eagle medium or RPMI-1640 supplemented with l-glutamine, 
penicillin/streptomycin, and 10% fetal bovine serum (Hyclone).
siRNA. The custom library was synthesized by Thermo Fisher Scientific as 
ON-TARGETplus siRNA. The in vivo experiments were conducted using 
standard siRNA.
mRNA quantitation. 15,000 cells per well were seeded in 96-well plates 
(Falcon) and transfected with 5 nM siRNA using HiPerFect Transfection 
Reagent (QIAGEN). After 48 h, RNA was collected and reverse transcribed 
using the Power SYBR Green Cells-to-CT kit (Invitrogen). Real-time 
PCR was performed on an Applied Biosystems 7500 using the following 
primer pairs (mismatches between M1 and M2 isoforms are underlined, and 
Tata binding protein [TBP] was used for normalization): PKM1/M2 forward: 
5-CATTGATTCACCACCCATCA-3; PKM1/M2 reverse: 5-AGAC-
GAGCCACATTCATTCC-3; PKM1 forward: 5-CGAGCCTCAAGT-
CACTCCAC-3; PKM1 reverse: 5-GTGAGCAGACCTGCCAGACT-3; 
PKM2 forward: 5-ATTATTTGAGGAACTCCGCCGCCT-3; PKM2 
reverse: 5-ATTCCGGGTCACAGCAATGATGG-3; TBP forward: 5-GGA-
GAGTTCTGGGATTGTAC-3; and TBP reverse: 5-CTTATCCTCATG-
ATTACCGCAG-3.
Western blot analysis. 250,000 cells per well were seeded in 6-well plates 
(Falcon) and transfected with 5 nM siRNA using HiPerFect Transfection 
Reagent (QIAGEN). After 48 h, the cells were lysed, the supernatant was 
quantitated, and the protein was boiled in 4× SDS sample buffer and run on 
4–12% gradient Bis-Tris gels (Invitrogen). Proteins were transferred to nitro-
cellulose, and Western blots were performed using rabbit monoclonal anti-
PKM1/M2 (Cell Signaling Technology), rabbit polyclonal anti-PKM2 (Cell 
Signaling Technology), and mouse monoclonal anti-Vinculin (Sigma-Aldrich).
Cell viability analysis. 5,000 cells per well were seeded in 96-well plates 
(Falcon) and transfected with 5 nM siRNA using HiPerFect Transfection 
Reagent (QIAGEN). Cell viability was determined at 144 h by CellTiter-Glo 
or GF-AFC (Promega). To retain knockdown of PKM2, siRNA transfection 
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